Jinfeng Huang1,2, Zhenhua Qi1, Min Chen3, Ting Xiao3, Jian Guan3, Meijuan Zhou2, Qi Wang1, Zhongwu Lin4, Zhidong Wang1. 1. Department of Radiobiology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China. 2. Department of Radiation Medicine, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510080, China. 3. Department of Radiotherapy, Nanfang Hospital, Southern Medical University, Guangzhou 510080, China. 4. Science Research Management Department of the Academy of Military Sciences, Beijing 100091, China.
Abstract
BACKGROUND: Fast and reliable biomarkers are needed to distinguish whether individuals were exposed or not to radiation and assess radiation dose, and to predict the severity of radiation damage in a large-scale radiation accident. Serum amyloid A1 (SAA1) is a protein induced by multiple factors including inflammatory. Therefore, this study aimed at exploring the role of SAA1 in the radiation dose estimation and lethality prediction after radiation. METHODS: C57BL/6J female mice were exposed to total body irradiation (TBI) at different doses and time points and amifostine, a drug used to reduce the side effects of radiotherapy, was injected before irradiation. Patients with nasopharyngeal carcinoma subjected to radiotherapy were used as the irradiation model in humans. RESULTS: A moderate SAA1 increase was observed at 6 hours in serum samples from irradiated mice at all doses used, with a peak at 12 hours, then decreased to day 3 after exposure. A second SAA1 increase was observed from day 5 to 7, which was associated to subsequent lethality. Treatment with amifostine before irradiation could prevent mice death and inhibit the second SAA1 increase. SAA1 increase after radiation was confirmed in human serum of nasopharyngeal carcinoma patients after radiotherapy. CONCLUSIONS: Serum SAA1 levels could represent a biomarker for radiation dose estimation and its second increase might be a useful lethality indicator after radiation in a mouse model. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Fast and reliable biomarkers are needed to distinguish whether individuals were exposed or not to radiation and assess radiation dose, and to predict the severity of radiation damage in a large-scale radiation accident. Serum amyloid A1 (SAA1) is a protein induced by multiple factors including inflammatory. Therefore, this study aimed at exploring the role of SAA1 in the radiation dose estimation and lethality prediction after radiation. METHODS: C57BL/6J female mice were exposed to total body irradiation (TBI) at different doses and time points and amifostine, a drug used to reduce the side effects of radiotherapy, was injected before irradiation. Patients with nasopharyngeal carcinoma subjected to radiotherapy were used as the irradiation model in humans. RESULTS: A moderate SAA1 increase was observed at 6 hours in serum samples from irradiated mice at all doses used, with a peak at 12 hours, then decreased to day 3 after exposure. A second SAA1 increase was observed from day 5 to 7, which was associated to subsequent lethality. Treatment with amifostine before irradiation could prevent mice death and inhibit the second SAA1 increase. SAA1 increase after radiation was confirmed in human serum of nasopharyngeal carcinoma patients after radiotherapy. CONCLUSIONS: Serum SAA1 levels could represent a biomarker for radiation dose estimation and its second increase might be a useful lethality indicator after radiation in a mouse model. 2019 Annals of Translational Medicine. All rights reserved.
Authors: Eileen Pernot; Janet Hall; Sarah Baatout; Mohammed Abderrafi Benotmane; Eric Blanchardon; Simon Bouffler; Houssein El Saghire; Maria Gomolka; Anne Guertler; Mats Harms-Ringdahl; Penny Jeggo; Michaela Kreuzer; Dominique Laurier; Carita Lindholm; Radhia Mkacher; Roel Quintens; Kai Rothkamm; Laure Sabatier; Soile Tapio; Florent de Vathaire; Elisabeth Cardis Journal: Mutat Res Date: 2012-06-04 Impact factor: 2.433
Authors: Nicholas Dainiak; Robert Nicolas Gent; Zhanat Carr; Rita Schneider; Judith Bader; Elena Buglova; Nelson Chao; C Norman Coleman; Arnold Ganser; Claude Gorin; Martin Hauer-Jensen; L Andrew Huff; Patricia Lillis-Hearne; Kazuhiko Maekawa; Jeffrey Nemhauser; Ray Powles; Holger Schünemann; Alla Shapiro; Leif Stenke; Nelson Valverde; David Weinstock; Douglas White; Joseph Albanese; Viktor Meineke Journal: Disaster Med Public Health Prep Date: 2011-10-10 Impact factor: 1.385
Authors: Jamie K Waselenko; Thomas J MacVittie; William F Blakely; Nicki Pesik; Albert L Wiley; William E Dickerson; Horace Tsu; Dennis L Confer; C Norman Coleman; Thomas Seed; Patrick Lowry; James O Armitage; Nicholas Dainiak Journal: Ann Intern Med Date: 2004-06-15 Impact factor: 25.391
Authors: Daniel O Thomas-Rüddel; Bernhard Poidinger; Matthias Kott; Manfred Weiss; Konrad Reinhart; Frank Bloos Journal: Crit Care Date: 2018-05-13 Impact factor: 9.097